NVAX - NovavaxAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $170.29 | Open | $175.46 |
| Volume | 4.2M | Market Cap | 9.98B |
| Yield | Last Dividend |
| Novavax Inks Vaccine Deals In Japan, Ind... | 08/09/20 |
| Novavax announced a partnership with Takeda Pharmaceutical to sell up to 250 million doses of NVX???CoV2373, its COVID-19 vaccine candidate, a year in... | |
| COVID-19 Vaccine to Cost Less Than Rs 25... | 08/07/20 |
| Pune based Serum Institute of India (SII) announced on Friday, 7 August, that it would introduce candidate vaccines from AstraZeneca and Novavax for C... | |
| Better Coronavirus Stock: Novavax or Vax... | 08/07/20 |
| Novavax is further along in the race to develop a coronavirus vaccine, but don???t count out Vaxart just yet. | |
| The Daily Biotech Pulse: Novavax Vaccine... | 08/07/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVI... | |
| Coronavirus vaccine: Serum Institute tie... | 08/07/20 |
| SII has already joined hands with Astra Zeneca and Novavax to develop their coronavirus candidates | |
| Serum Institute of India to get $150 mil... | 08/07/20 |
| "The candidate vaccines, including those from AstraZeneca and Novavax, will be priced at $3 per dose and will be made available in 92 countries in GAV... | |
| Takeda to make Novavax's COVID-19 vaccin... | 08/07/20 |
| Takeda Pharmaceutical will manufacture and sell up to 250 million doses of Novavax Inc's COVID-19 vaccine candidate in Japan every year, the two compa... | |
| Takeda Pharmaceutical : & Novavax Announ... | 08/07/20 |
| Takeda Pharmaceutical Co Ltd: * NOVAVAX AND TAKEDA ANNOUNCE COLLABORATION FOR NOVAVAX' COVID-19 VACCINE CANDIDATE IN JAPAN * SEES CAPACITY TO MANUFACT... | |
| Novavax and Takeda Announce Collaboratio... | 08/07/20 |
| Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in JapanMatrix-M adjuvant to be supplied from??? | |
| Serum Institute to price Covid-19 vaccin... | 08/07/20 |
| Mumbai: Serum Institute of India (SII), the world???s largest vaccine manufacturer by volume has set the price of Covid-19 vaccine for $3 per dose to ... | |
| Coronavirus vaccine: Novavax, Serum Inst... | 08/07/20 |
| Coronavirus vaccine news update: Serum Institute of India would have exclusive rights for the supply of the Novavax COVID-19 vaccine in India | |
| Serum Institute, Novavax in covid vaccin... | 08/06/20 |
| The agreement is expected to support minimum of 100 crore doses of Novavax's covid vaccine for India and low- and middle-income countries | |
| Serum Institute inks deal with American ... | 08/06/20 |
| Serum Institute of India (SII), which has signed deal to manufacture Oxford-AstraZeneca coronavirus vaccine, has now entered into an agreement with Am... | |
| Maryland-based company generates promisi... | 08/06/20 |
| On Tuesday, Aug. 4, the Maryland-based company, Novavax, released its data from phase one of its clinical trials for a new vaccine candidate for COVID... | |
| Dr. Fauci: We might have tens of million... | 08/06/20 |
| Dr. Anthony Fauci believes an effective coronavirus vaccine will be granted approval by late 2020. Fauci recently said that we could have tens of mill... | |
| Top Analyst Upgrades and Downgrades: Bio... | 08/06/20 |
| No summary available. | |
| Coronavirus: Serum Institute of India si... | 08/06/20 |
| The Serum Institute will get exclusive rights for the vaccine in India for the entire duration of the agreement. | |
| US pours billions into coronavirus vacci... | 08/06/20 |
| It???s the question we all want to know the answer to: when will a coronavirus vaccine be ready? | |
| Novavax Inks Deal With India's Serum Ins... | 08/06/20 |
| Novavax, Inc (NASDAQ: NVAX ) disclosed Wednesday it had entered into an agreement with the Serum Institute of India Private Limited for development, d... | |
| These 3 Covid-19 vaccines have been in t... | 08/05/20 |
| The US government is pouring billions into Covid-19 vaccines, and candidates from three companies are moving along quickly: Moderna, Pfizer and Novava... | |
| COVID-19 vaccine: Novavax inks supply de... | 08/05/20 |
| On Tuesday, Novavax reported that its experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early... | |
| Covid-19 vaccine: Serum India ties up wi... | 08/05/20 |
| According to a report by news agency Reuters, apart from the exclusive production and development license of the vaccine in India, Serum institute has... | |
| Novavax signs coronavirus vaccine supply... | 08/05/20 |
| Novavax Inc has signed a deal with the Serum Institute of India for the development and commercialisation of the Novavax coronavirus vaccine candidate... | |
| Coronavirus Live Updates: Novavax Signs ... | 08/05/20 |
| Novavax Inc said it has signed a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID... | |
| JPMorgan Turns Bullish On Novavax After ... | 08/05/20 |
| Novavax, Inc. (NASDAQ: NVAX ) announced positive results from the Phase 1 portion of the Phase 1/2 trial of its coronavirus vaccine candidate, and it ... | |
| Buy rating | 08/06/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $132.00 to $290.00 | |
| Strong Buy rating | 08/05/20 |
| JP Morgan upgrades from Neutral to Overweight rating and raises Price Target from $105.00 to $275.00 | |
| Sell rating | 08/05/20 |
| Ladenburg Thalmann downgrades from Neutral to Sell rating and announces Price Target of $105.00 | |
| Buy rating | 08/05/20 |
| B. Riley FBR maintains Buy rating and raises Price Target from $184.00 to $257.00 | |
| Buy rating | 07/16/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $101.00 to $132.00 | |
| Hold rating | 07/08/20 |
| Ladenburg Thalmann downgrades from Buy to Neutral rating and raises Price Target from $50.00 to $105.00 | |
| Buy rating | 06/29/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $50.00 to $101.00 | |
| Buy rating | 06/29/20 |
| B. Riley FBR maintains Buy rating and raises Price Target from $74.00 to $106.00 | |
| Strong Buy rating | 06/19/20 |
| Cantor Fitzgerald maintains Overweight rating and raises Price Target from $45.00 to $88.00 | |
| Hold rating | 06/05/20 |
| JP Morgan upgrades from Underweight to Neutral rating and announces Price Target of $46.00 | |
| Buy rating | 05/28/20 |
| B. Riley FBR maintains Buy rating and raises Price Target from $53.00 to $61.00 | |
| Buy rating | 05/18/20 |
| B. Riley FBR maintains Buy rating and raises Price Target from $43.00 to $53.00 | |
| Strong Buy rating | 05/13/20 |
| and raises Price Target from $23.00 to $45.00 | |
| Date | Today (AMC) | Est. (EPS/Rev.) | ($0.42)/ 39.58M |
| Actual (EPS/Rev.) | / | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Pennies | Mmkt0652 | 87.00 % | Subscribe |
| Tech Trades | Tech Trades | 84.00 % | Follow |
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Option Superstars | James Catzen | 76.00 % | Subscribe |
| Arbitrage Trade Analytics | Royce Wells | 71.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
